Acute myeloid leukemia echocardiograph and ultrasound: Difference between revisions
Shyam Patel (talk | contribs) |
Shyam Patel (talk | contribs) No edit summary |
||
Line 9: | Line 9: | ||
==Echocardiograph and ultrasound== | ==Echocardiograph and ultrasound== | ||
*'''Echocardiograph''': An echocardiogram is an essential imaging modality in patients with acute myeloid leukemia receiving anthracycline chemotherapy.<ref name="pmid22917553">{{cite journal| author=Neilan TG, Coelho-Filho OR, Pena-Herrera D, Shah RV, Jerosch-Herold M, Francis SA et al.| title=Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. | journal=Am J Cardiol | year= 2012 | volume= 110 | issue= 11 | pages= 1679-86 | pmid=22917553 | doi=10.1016/j.amjcard.2012.07.040 | pmc=3496816 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22917553 }} </ref> Patients who will be receiving anthracycline-based therapy require a baseline echocardiogram to assess the ejection fraction prior to therapy. Anthracyclines are known to cause cardiac toxicity (specifically cardiomyopathy with cumulative anthracycline doses above 500mg/m2). An echocardiogram should be obtained every three months while on therapy with anthracycline. Echocardiogram also applies particularly to cases of high-risk acute promyelocytic leukemia, in which case the standard of care is to give anthracycline along with all-''trans'' retinoic acid. | *'''Echocardiograph''': An echocardiogram is an essential imaging modality in patients with acute myeloid leukemia receiving anthracycline chemotherapy.<ref name="pmid22917553">{{cite journal| author=Neilan TG, Coelho-Filho OR, Pena-Herrera D, Shah RV, Jerosch-Herold M, Francis SA et al.| title=Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. | journal=Am J Cardiol | year= 2012 | volume= 110 | issue= 11 | pages= 1679-86 | pmid=22917553 | doi=10.1016/j.amjcard.2012.07.040 | pmc=3496816 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22917553 }} </ref> Patients who will be receiving anthracycline-based therapy require a baseline echocardiogram to assess the ejection fraction prior to therapy. Anthracyclines are known to cause cardiac toxicity (specifically cardiomyopathy with cumulative anthracycline doses above 500mg/m2). An echocardiogram should be obtained every three months while on therapy with anthracycline. Echocardiogram also applies particularly to cases of high-risk acute promyelocytic leukemia, in which case the standard of care is to give anthracycline along with all-''trans'' retinoic acid. | ||
*'''Ultrasound''': This is useful for diagnosis of lower extremity thrombosis, which commonly occurs in patients with acute myeloid leukemia. | *'''Ultrasound''': This is useful for diagnosis of lower extremity thrombosis, which commonly occurs in patients with acute myeloid leukemia.<ref name="pmid26973753">{{cite journal| author=Zitek T, Baydoun J, Yepez S, Forred W, Slattery DE| title=Mistakes and Pitfalls Associated with Two-Point Compression Ultrasound for Deep Vein Thrombosis. | journal=West J Emerg Med | year= 2016 | volume= 17 | issue= 2 | pages= 201-8 | pmid=26973753 | doi=10.5811/westjem.2016.1.29335 | pmc=4786247 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26973753 }} </ref> |
Revision as of 21:48, 31 October 2018
Acute myeloid leukemia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Acute myeloid leukemia echocardiograph and ultrasound On the Web |
American Roentgen Ray Society Images of Acute myeloid leukemia echocardiograph and ultrasound |
FDA on Acute myeloid leukemia echocardiograph and ultrasound |
CDC on Acute myeloid leukemia echocardiograph and ultrasound |
Acute myeloid leukemia echocardiograph and ultrasound in the news |
Blogs on Acute myeloid leukemia echocardiograph and ultrasound |
Risk calculators and risk factors for Acute myeloid leukemia echocardiograph and ultrasound |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Overview
Additional imaging studies that can be useful in acute promyelocytic leukemia include echocardiogram which is useful for assessing cardiac function in patients receiving anthracycline chemotherapy.
Echocardiograph and ultrasound
- Echocardiograph: An echocardiogram is an essential imaging modality in patients with acute myeloid leukemia receiving anthracycline chemotherapy.[1] Patients who will be receiving anthracycline-based therapy require a baseline echocardiogram to assess the ejection fraction prior to therapy. Anthracyclines are known to cause cardiac toxicity (specifically cardiomyopathy with cumulative anthracycline doses above 500mg/m2). An echocardiogram should be obtained every three months while on therapy with anthracycline. Echocardiogram also applies particularly to cases of high-risk acute promyelocytic leukemia, in which case the standard of care is to give anthracycline along with all-trans retinoic acid.
- Ultrasound: This is useful for diagnosis of lower extremity thrombosis, which commonly occurs in patients with acute myeloid leukemia.[2]
- ↑ Neilan TG, Coelho-Filho OR, Pena-Herrera D, Shah RV, Jerosch-Herold M, Francis SA; et al. (2012). "Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines". Am J Cardiol. 110 (11): 1679–86. doi:10.1016/j.amjcard.2012.07.040. PMC 3496816. PMID 22917553.
- ↑ Zitek T, Baydoun J, Yepez S, Forred W, Slattery DE (2016). "Mistakes and Pitfalls Associated with Two-Point Compression Ultrasound for Deep Vein Thrombosis". West J Emerg Med. 17 (2): 201–8. doi:10.5811/westjem.2016.1.29335. PMC 4786247. PMID 26973753.